SCHEMBL5372829

SCHEMBL5372829

O=C(O)c1ccc(NC(=S)NN=Cc2cccc(-c3ccc(F)cc3)c2O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.54
SMN1; SMN2 Q16637 7/20 0.54
GAA P10253 6/20 0.54
KDM4E B2RXH2 6/20 0.54
HDAC8 Q9BY41 2/20 0.51
RAB9A P51151 6/20 0.47
NPC1 O15118 6/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 7/20 0.46
MEN1 O00255 6/20 0.46
PKM P14618 2/20 0.46
MITF O75030 1/20 0.46
PAX8 Q06710 1/20 0.46
KLF5 Q13887 1/20 0.46
LMNA P02545 5/20 0.45
HTT P42858 5/20 0.45
NPSR1 Q6W5P4 1/20 0.44
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
ALDH1A1 P00352 5/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5372825 1.00 MAPT (0.54) MAPTSMN1; SMN2GAAKDM4EHDAC8
SCHEMBL5365381 0.85 GAA (0.54) MAPTSMN1; SMN2GAAKDM4EHDAC8
SCHEMBL5365385 0.85 GAA (0.54) MAPTSMN1; SMN2GAAKDM4EHDAC8
SCHEMBL5365026 0.84 MAPT (0.52) MAPTSMN1; SMN2GAAKDM4EHDAC8
SCHEMBL5365029 0.84 MAPT (0.52) MAPTSMN1; SMN2GAAKDM4EHDAC8
SCHEMBL5365939 0.84 SMN1; SMN2 (0.50) MAPTSMN1; SMN2GAAKDM4EHDAC8
SCHEMBL5365944 0.84 SMN1; SMN2 (0.50) MAPTSMN1; SMN2GAAKDM4EHDAC8
SCHEMBL5365812 0.82 MAPT (0.55) MAPTSMN1; SMN2GAAKDM4EHDAC8
SCHEMBL5365816 0.82 MAPT (0.55) MAPTSMN1; SMN2GAAKDM4EHDAC8
SCHEMBL5357962 0.82 MAPT (0.52) MAPTSMN1; SMN2GAAKDM4EHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP claimed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US claimed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP claimed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO claimed
US-7241783-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-07-10 US disclosed
EP-1349613-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2005-09-21 EP disclosed
US-20040058990-A1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION 2004-03-25 US disclosed
EP-1349613-A2 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-10-08 EP disclosed
WO-2002049413-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058990-A1 Thrombopoietin mimetics MPL, THPO, TEK MAPT 4635/4885SMN1; SMN2 2721/4885GAA 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.